Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data From Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Why It Matters

Durable remission data bolsters obefazimod’s value proposition in the roughly $15 billion ulcerative colitis market, and the robust cash position gives Abivax the financial runway to complete late‑stage trials and pursue commercialization.

Key Takeaways

• 68% of 130 UC patients in remission after 144 weeks of obefazimod.
• Cash and equivalents €491.6 M (~$540 M) give runway to Q4 2027.
• R&D expenses rose to €49.5 M, up €10.2 M YoY.
• Phase 3 ABTECT UC trial results slated for late Q2 2026.
• No new safety signals after up to seven years of treatment.

Pulse Analysis

Ulcerative colitis (UC) remains a major therapeutic challenge, with patients seeking long‑lasting disease control beyond short‑term steroids and biologics. Obefazimod, Abivax’s oral small‑molecule candidate, targets the body’s innate regulatory pathways, offering a novel mechanism that could fill a gap in the $15 billion global UC market. Industry analysts are watching how oral agents differentiate themselves on durability, safety, and ease of administration, especially as payers prioritize cost‑effective, outpatient solutions.

The three‑year interim analysis from Study 108 provides compelling evidence of durability: 68% of the 130‑patient cohort maintained clinical remission at week 144, and 80% completed the full evaluation period. Importantly, the trial reported no new safety signals after up to seven years of continuous exposure, reinforcing the drug’s tolerability profile. These outcomes set a strong precedent for the upcoming Phase 3 ABTECT maintenance trial, whose late‑Q2 2026 read‑out could validate obefazimod as a viable long‑term maintenance therapy and potentially accelerate regulatory filings.

Financially, Abivax entered Q1 2026 with €491.6 million (≈$540 million) in cash and short‑term investments, extending its runway into the fourth quarter of 2027. The company’s R&D spend rose to €49.5 million, reflecting expanded work on new indications such as Crohn’s disease, while G&A costs fell, improving operational efficiency. With the Phase 3 read‑out on the horizon and a solid balance sheet, investors view Abivax as positioned to capture market share should obefazimod meet its efficacy and safety milestones, making the next six months critical for valuation upside.